NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

Predictors of Health-Related QOL in Adults With CLL or Small Lymphocytic Lymphoma

RecruitingN/A

Sponsor: H. Lee Moffitt Cancer Center and Research Institute

Conditions: Small Lymphocytic Lymphoma (SLL), Chronic Lymphocytic Leukemia (CLL)

Interventions: Bruton's tyrosine kinase inhibitor, B-Cell Lymphoma 2 Protein Inhibitor

Countries: United States

The study aims to improve our understanding of how quality of life, fatigue, and symptoms change over 2 years when participants are treated for chronic lymphocytic leukemia or small lymphocytic lymphoma. We will compare two types of treatment to help future patients with chronic lymphocytic leukemia or small lymphocytic lymphoma know what to anticipate.

Eligibility overview

Sex: ALL

Age: 18 Years to —

Healthy volunteers: No

Study type: OBSERVATIONAL

Eligibility criteria

Inclusion Criteria:

* All patients with pathology-confirmed diagnoses of CLL who are within seven days of starting treatment with a BTKi +/- an anti-CD 20 monoclonal antibody or BCL2i with Obinutuzumab treatment will be included.
* Subjects must be able to read and speak English or Spanish at the 8th grade level.

Exclusion Criteria:

* Patients with dementia, traumatic brain injury, or individuals with central nervous system involvement of their leukemia will be excluded from study participation.

Locations (1)

Tampa, Florida, United States